Biocon Biologics said it has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023.
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris. Since the agreement closed in November 2022, Biocon Biologics has executed a robust integration plan to ensure a seamless transition of partners, people, systems, and processes.
Biocon Biologics has achieved many “firsts” in the industry including the first to receive approval of bTrastuzumab and bPegfilgrastim as well as interchangeable bGlargine in the United States. Serving over 5.7M patients annually, Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar across multiple therapies, including four in the United States and six in Canada, with a robust pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas.
With the completion of the North America integration, the existing commercialized portfolio of biosimilars, Ogiviri® (bTrastuzumab), Fulphila® (bPegfilgrastim), Semglee® (Insulin Glargine) and Hulio®* (bAdalimumab), is now incorporated into Biocon Biologics’ commercial organization in the United States. In addition to these products, Kirsty®(Aspart) and Abevmy® (Bevacizumab) will also be available in Canada.
As a result of the completion of this integration, Biocon Biologics is expected to grow its employee population to over 150 employees in North America by the end of the year.
Also published on Medium.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
